<DOC>
	<DOCNO>NCT00387088</DOCNO>
	<brief_summary>The objective study evaluate long-term ( one year ) efficacy safety tiotropium deliver Respimat inhaler patient COPD . Specifically , study examine effect treatment COPD exacerbation .</brief_summary>
	<brief_title>Tiotropium / Respimat One Year Study COPD .</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>1 . Male female 2 . At least 40 year old 3 . Smoker exsmoker 4 . Smoking history &gt; 10 packyears 5 . Forced Expiratory Volume 1 Second ( FEV1 ) &lt; 60 % predict 1 . Recent history myocardial infarction , lifethreatening cardiac arrhythmia hospitalisation cardiac failure 2 . History asthma allergic condition . 3 . Malignancy require treatment within past 5 year 4 . Lifethreatening pulmonary obstruction , cystic fibrosis clinically evident bronchiectasis 5 . Known active tuberculosis 6 . Known hypersensitivity anticholinergic drug .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
</DOC>